Crossmark Global Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $953K | Buy |
1,528
+286
| +23% | +$195K | 0.01% | 640 |
|
|
2026
Q1 | $960K | Sell |
1,242
-5
| -0.4% | -$3.83K | 0.01% | 619 |
|
|
2025
Q4 | $963K | Sell |
1,247
-1,061
| -46% | -$721K | 0.01% | 618 |
|
|
2025
Q3 | $1.3M | Buy |
2,308
+42
| +2% | +$23.7K | 0.02% | 558 |
|
|
2025
Q2 | $1.19M | Sell |
2,266
-142
| -6% | -$79.3K | 0.02% | 557 |
|
|
2025
Q1 | $1.53M | Sell |
2,408
-246
| -9% | -$169K | 0.03% | 487 |
|
|
2024
Q4 | $1.89M | Buy |
2,654
+92
| +4% | +$77.2K | 0.03% | 409 |
|
|
2024
Q3 | $2.69M | Sell |
2,562
-73
| -3% | -$81.2K | 0.05% | 342 |
|
|
2024
Q2 | $2.77M | Sell |
2,635
-3
| -0.1% | -$2.91K | 0.05% | 333 |
|
|
2024
Q1 | $2.54M | Sell |
2,638
-42
| -2% | -$39.9K | 0.05% | 364 |
|
|
2023
Q4 | $2.35M | Sell |
2,680
-33
| -1% | -$27.2K | 0.05% | 357 |
|
|
2023
Q3 | $2.27M | Sell |
2,713
-73
| -3% | -$57.4K | 0.05% | 358 |
|
|
2023
Q2 | $2.08M | Buy |
2,786
+51
| +2% | +$39.3K | 0.04% | 403 |
|
|
2023
Q1 | $2.25M | Sell |
2,735
-134
| -5% | -$101K | 0.05% | 375 |
|
|
2022
Q4 | $2.07M | Buy |
2,869
+32
| +1% | +$23.6K | 0.05% | 386 |
|
|
2022
Q3 | $1.95M | Sell |
2,837
-265
| -9% | -$167K | 0.05% | 368 |
|
|
2022
Q2 | $1.83M | Buy |
3,102
+53
| +2% | +$34.5K | 0.05% | 403 |
|
|
2022
Q1 | $2.13M | Sell |
3,049
-199
| -6% | -$126K | 0.05% | 393 |
|
|
2021
Q4 | $2.05M | Buy |
3,248
+210
| +7% | +$129K | 0.04% | 405 |
|
|
2021
Q3 | $1.84M | Sell |
3,038
-43
| -1% | -$26.7K | 0.04% | 410 |
|
|
2021
Q2 | $1.72M | Sell |
3,081
-219
| -7% | -$111K | 0.04% | 436 |
|
|
2021
Q1 | $1.56M | Buy |
3,300
+160
| +5% | +$77.9K | 0.04% | 448 |
|
|
2020
Q4 | $1.52M | Buy |
3,140
+2
| +0.1% | +$1.08K | 0.04% | 448 |
|
|
2020
Q3 | $1.76M | Buy |
3,138
+66
| +2% | +$40K | 0.05% | 378 |
|
|
2020
Q2 | $1.92M | Buy |
3,072
+523
| +21% | +$297K | 0.06% | 348 |
|
|
2020
Q1 | $1.25M | Sell |
2,549
-215
| -8% | -$88.7K | 0.04% | 401 |
|
|
2019
Q4 | $1.04M | Sell |
2,764
-37
| -1% | -$12.4K | 0.03% | 549 |
|
|
2019
Q3 | $777K | Sell |
2,801
-655
| -19% | -$194K | 0.02% | 608 |
|
|
2019
Q2 | $1.08M | Sell |
3,456
-2,023
| -37% | -$673K | 0.03% | 538 |
|
|
2019
Q1 | $2.25M | Sell |
5,479
-362
| -6% | -$149K | 0.06% | 339 |
|
|
2018
Q4 | $2.18M | Sell |
5,841
-1,753
| -23% | -$642K | 0.07% | 327 |
|
|
2018
Q3 | $3.07M | Sell |
7,594
-858
| -10% | -$327K | 0.08% | 284 |
|
|
2018
Q2 | $2.92M | Buy |
8,452
+1
| +0% | +$313 | 0.08% | 287 |
|
|
2018
Q1 | $2.91M | Sell |
8,451
-872
| -9% | -$303K | 0.08% | 313 |
|
|
2017
Q4 | $3.5M | Buy |
9,323
+1,755
| +23% | +$711K | 0.08% | 287 |
|
|
2017
Q3 | $3.38M | Buy |
+7,568
| New | +$3.6M | 0.09% | 276 |
|
|
2016
Q3 | $3.38M | Buy |
+7,568
| New | +$3.04M | 0.09% | 276 |
|
Other funds holding REGN
Crossmark Global Holdings's REGN Position: Q2 2026 in Review
Crossmark Global Holdings increased its Regeneron Pharmaceuticals (REGN) stake by 23% in Q2 2026, buying an estimated $195K and bringing the position to 1,528 shares worth $953K. The position accounts for 0.01% of the portfolio, ranked #640.
Crossmark Global Holdings first reported a position in REGN in Q3 2016 and has held it in 37 quarters since. The position peaked at $3.5M in Q4 2017. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Crossmark Global Holdings held 1,528 shares of Regeneron Pharmaceuticals worth $953K as of Q2 2026.
- Crossmark Global Holdings bought 286 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $195K.
- Regeneron Pharmaceuticals made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #640 holding.
- Crossmark Global Holdings first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's Regeneron Pharmaceuticals position peaked at $3.5M in Q4 2017.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.